Search

Your search keyword '"Inaba, Tomoki"' showing total 32 results
Start Over Author "Inaba, Tomoki" Publication Year Range Last 3 years
32 results on '"Inaba, Tomoki"'

2. Long-term outcomes of patients with primary intestinal follicular lymphoma managed with watch-and-wait strategy

Author

Iwamuro, Masaya, Tanaka, Takehiro, Ennishi, Daisuke, Matsueda, Kazuhiro, Yoshioka, Masao, Miyahara, Koji, Sakaguchi, Chihiro, Nishimura, Mamoru, Nagahara, Teruya, Mannami, Tomohiko, Takenaka, Ryuta, Oka, Shohei, Inoue, Masafumi, Takimoto, Hidetaka, Inaba, Tomoki, Kobayashi, Sayo, Toyokawa, Tatsuya, Tsugeno, Hirofumi, Suzuki, Seiyuu, Sawada, Sachiko, Tanaka, Shouichi, Tsuzuki, Takao, and Okada, Hiroyuki

Published
2023
Full Text
View/download PDF

3. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial

Author

Oliinyk, Oleksandr, Bilianskyi, Leonid, Gniady-Jastrzebska, Jadwiga, Petryka, Robert, Arlukowicz, Tomasz, Gietka, Piotr, Zmudzinski, Marcin, Mumtaz, Syed, Wolf, Douglas, Wojcik, Katarzyna, Duvall, George, Augustyn, Monika, Filip, Rafal, Tarabar, Dino, Tkachev, Alexander, Seidler, Ursula, Zittan, Eran, Pokrotnieks, Juris, Shchukina, Oksana, Machavariani, Andro, Loy, Laura, Abu-farsakh, Niazy, Marina, Pesegova, Sreckovic, Slobodan, Laclav, Martin, Wei, Shu-Chen, Suiter, Daniel, Borsuk, Aleksey, Hebuterne, Xavier, Buning, Carsten, Lahat-Zok, Adi, Danilkiewicz, Wit, Frysna, Bernadetta, Jovicic, Ivana, Datsenko, Olena, Guram, Maninder, Jain, Animesh, Rashid, Zahid, Heeren, Sonja, Shulga, Natallia, Timkin, Ivan, Gornjakovic, Srdjan, Lukas, Milan, Altwegg, Romain, Desjeux, Ariadne, Reimund, Jean-Marie, Giorgadze, Manana, Jochum, Christoph, Ito, Hiroaki, Nakai, Katsuhiko, Takagi, Tomohisa, Zaha, Osamu, Choi, Changhwan, Kim, Taeoh, Lee, Jonghun, Stundiene, Ieva, Hilmi, Ida Normiha, Hj Md Said, Rosaida, Leszczyszyn, Jaroslaw, Abdulganieva, Diana, Fominykh, Yulia, Maksyashina, Svetlana, Balaz, Jozef, Van Domselaar, Manuel, Kav, Taylan, Dennis, Patrick, Henry, Patricia, Holmes, Robert, Johnson, Christopher, McBride, Matthew, Sarles, Harry, Moore, Gregory, Yakubtsevich, Ruslan, Muls, Vinciane, Trbojevic, Stevan, Afif, Waqqas, Bernstein, Charles, Klarin, Ivo, Serclova, Zuzana, Volfova, Miroslava, Desreumaux, Pierre, Gilletta de Saint Joseph, Cyrielle, Roblin, Xavier, Vuitton, Lucine, Chelidze, Kakhaber, Kuehbacher, Tanja, Koutroubakis, Ioannis, Cicala, Michele, Fries, Walter, Gasbarrini, Antonio, Aoyama, Nobuo, Hayashi, Yoshito, Hirai, Fumihito, Horiki, Norkiyuki, Hoshi, Namiko, Inaba, Tomoki, Hiroyasu, Ishida, Maemoto, Atsuo, Matsumoto, Takayuki, Matsushima, Kayoko, Motoya, Satoshi, Taruishi, Masaki, Rashid, Mohammed, Chun, Jaeyoung, Kim, Young-Ho, Park, Dong Il, Sharara, Ala, Jonaitis, Laimas, Deriban, Gjorgi, Brooker, James, Gawdis-Wojnarska, Beata, Wozniak-Stolarska, Barbara, Andreev, Pavel, Simanenkov, Vladimir, Trofimov, Vasiliy, Jovanovic, Igor, Zdravkovic, Natasa, Aldeguer i Mante, Xavier, Hernandez Ramirez, Vicent, Akpinar, Hale, Celebi, Gurkan, Hamzaoglu, Hulya, Fernandez, Juan, Kamath, Jayaprakash, Palekar, Nicole, Pruthi, Jatinder S., Rausher, David, Ritter, Timothy, Danese, Silvio, Panaccione, Remo, Feagan, Brian G, Afzali, Anita, Rubin, David T, Sands, Bruce E, Reinisch, Walter, Panés, Julián, Sahoo, Aparna, Terry, Natalie A, Chan, Daphne, Han, Chenglong, Frustaci, Mary Ellen, Yang, Zijiang, Sandborn, William J, Hisamatsu, Tadakazu, Andrews, Jane M, and D'Haens, Geert R

Published
2024
Full Text
View/download PDF

4. Effectiveness of second-look endoscopy after gastric endoscopic submucosal dissection in patients taking antithrombotic agents: a multicenter propensity score matching analysis

Author

Iwatsubo, Taro, Takeuchi, Toshihisa, Hakoda, Akitoshi, Fujiwara, Yasuhiro, Nagami, Yasuaki, Naito, Yuji, Dohi, Osamu, Tatsuta, Tetsuya, Sawaya, Manabu, Jin, Xiaoyi, Koike, Tomoyuki, Sugimoto, Mitsushige, Murata, Masaki, Hamada, Kenta, Okada, Hiroyuki, Kobara, Hideki, Chiyo, Taiga, Yoshida, Norimasa, Tomatsuri, Naoya, Inaba, Tomoki, Ishikawa, Shigenao, Nagahara, Akihito, Ueyama, Hiroya, Koizumi, Eriko, Iwakiri, Katsuhiko, Mizukami, Kazuhiro, Murakami, Kazunari, Furuta, Takahisa, Suzuki, Takahiro, Ogasawara, Naotaka, Kasugai, Kunio, Isomoto, Hajime, Kawaguchi, Koichiro, Shibagaki, Kotaro, Kataoka, Hiromi, Shimura, Takaya, Suzuki, Hidekazu, Nishizawa, Toshihiro, and Higuchi, Kazuhide

Published
2022
Full Text
View/download PDF

5. AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

Author

Motoya, Satoshi, Maemoto, Atsuo, Fujiya, Mikihiro, Ashida, Toshifumi, Goto, Mitsuru, Matsumoto, Takayuki, Suzuki, Yasuo, Hamahata, Yukihiro, Nakagawa, Tomoo, Kato, Naoya, Kato, Jun, Endo, Yutaka, Suzuki, Ryoichi, Matsuda, Koichiro, Ohmiya, Naoki, Katsushima, Shinji, Hosomi, Shuhei, Tarumi, Ken-ichi, Watanabe, Chiyuki, Saito, Mitsuru, Yokoyama, Yuichiro, Inaba, Tomoki, Sakata, Yasuhisa, Hongo, Hitoshi, Shibuya, Tomoyoshi, Kawakami, Kazuhiko, Kakuta, Yoichi, Irisawa, Atsushi, Yoshimura, Naoki, Fukuda, Katsuyuki, Shirai, Takayuki, Ichikawa, Hitoshi, Nagata, Junko, Suzuki, Takayoshi, Yokoyama, Kaoru, Tomidokoro, Takashi, Kojima, Yuichiro, Yamada, Masahiro, Yamamoto, Hideko, Yamamoto, Takayuki, Horiki, Noriyuki, Obata, Hirozumi, Inoue, Satoko, Tanaka, Shinji, Toyokawa, Tatsuya, Kunihiro, Masaki, Hisabe, Takashi, Ogata, Shinichi, Takeshima, Fuminao, Matsushima, Kayoko, Matsuhashi, Nobuyuki, Sakuraba, Hirotake, Iwabuchi, Masahiro, Tsuchiya, Akihiko, Uchiyama, Kan, Kanai, Takanori, Nakamura, Masanao, Yokoyama, Tadashi, Hida, Nobuyuki, Mitsuyama, Keiichi, Osada, Taro, Hiraoka, Sakiko, Tsuzuki, Tomoyuki, Masuo, Takashige, Hokari, Ryota, Kobayashi, Taku, Saruta, Masayuki, Araki, Masao, Araki, Hiroshi, Shimizu, Masahito, Kikuchi, Masakazu, Nishikawa, Takahiro, Takedatsu, Hidetoshi, Aoyagi, Kunihiko, Ochiai, Toshiaki, Toda, Nobuo, Mizokami, Yuji, Nagahori, Masakazu, Matsueda, Kazuhiro, Kino, Hitoshi, Kanamori, Akira, Suzuki, Tsunehiro, Sakurai, Toshiharu, Kudo, Masatoshi, Kitano, Atsuo, Hisamatsu, Tadakazu, Kumagai, Shinji, Ninomiya, Tomoyuki, Mori, Kenichiro, Yoshida, Shun-ichi, Goto, Mitsuhide, Matsuoka, Katsuyoshi, Watanabe, Mamoru, Ohmori, Toshihide, Nakajima, Koichi, Ishida, Tetsuya, Ishiguro, Yoh, Kanke, Kazunari, Kobayashi, Kiyonori, Hirai, Fumihito, Watanabe, Kenji, Mizusawa, Hidehiro, Kishida, Shuji, Miura, Yoshiharu, Ohta, Akira, Kajioka, Toshifumi, and Hibi, Toshifumi

Published
2022
Full Text
View/download PDF

6. Nonrecurrence Rate of Underwater EMR for ≤20-mm Nonampullary Duodenal Adenomas: A Multicenter Prospective Study (D-UEMR Study)

Author

Kanzaki, Hiromitsu, Inoue, Shuntaro, Miyake, Muneaki, Ohmori, Masayasu, Takeuchi, Yoji, Tani, Yasuhiro, Harada, Nobuyuki, Agatsuma, Nobukazu, Okada, Keijirou, Ikenouchi, Maiko, Nakatani, Yasuki, Uenoyama, Yoshito, Yamashita, Yukitaka, Ishikawa, Shigenao, Inaba, Tomoki, Miyahara, Koji, Moritou, Yuki, Nakagawa, Masahiro, Kitae, Hiroaki, Ishida, Tsugitaka, Naito, Yuji, Nishio, Akiyoshi, Shimatani, Masaaki, Kato, Ryo, Taki, Shinya, Mandai, Koichiro, Sanada, Kasumi, Nakase, Kojiro, Nebiki, Hiroko, Saito, Shunsuke, Wakatsuki, Toshiyuki, Nishimura, Naoyuki, Yamasaki, Yasushi, Uedo, Noriya, Akamatsu, Takuji, Kagawa, Tomo, Higashi, Reiji, Dohi, Osamu, Furukawa, Masanori, Takahashi, Yu, Inoue, Takuya, Tanaka, Shouichi, Takenaka, Ryuta, Iguchi, Mikitaka, Kawamura, Takuji, Tsuzuki, Takao, Yamasaki, Tomoaki, Yamashina, Takeshi, Nasu, Junichiro, Mannami, Tomohiko, Yamauchi, Atsushi, Matsueda, Kazuhiro, Aizawa, Shigeyuki, Mitsuhashi, Toshiharu, and Okada, Hiroyuki

Published
2022
Full Text
View/download PDF

8. The Risk of Metastatic Recurrence after Non-Curative Endoscopic Resection with Negative Deep Margins for Early Colorectal Cancer: Two-Center Retrospective Cohort Study.

Author

Yamauchi, Kenji, Inaba, Tomoki, Morimoto, Takeshi, Aya, Yusuke, Colvin, Hugh Shunsuke, Nagahara, Teruya, Ishikawa, Shigenao, Wato, Masaki, and Imagawa, Atsushi

Subjects
*ENDOSCOPIC surgery, *SURGICAL margin, *COLORECTAL cancer, *SURVIVAL rate, *COHORT analysis
Abstract

Introduction: Non-curative endoscopic resection of T1 colorectal cancer (CRC) carries a substantial risk of recurrence. However, previous studies have reported a significant proportion of cases in which the deep margin of endoscopic resection was positive for cancer due to the technical difficulties of colorectal endoscopic submucosal dissection (ESD). With the advancement of endoscopic technology and techniques resulting in the reduction of positive resection margins, it is important to reassess the long-term prognosis and major risk factors for recurrence in cases of negative deep margins. Methods: We conducted a retrospective cohort study of consecutive patients with T1 CRC who underwent endoscopic resection between January 2006 and December 2021 with negative deep margins. The histological findings of the resected specimens were analyzed to determine the risk factors associated with the primary outcomes of this study, including recurrence and cancer-related deaths. Results: The median age of the 190 patients was 70 years, of which 63% were male, and endoscopic treatment was performed in 64% by endoscopic mucosal resection and 36% by ESD. Eighty-two patients were in the curative resection (CR) group and 108 were in the non-curative resection (NCR) group, wherein the latter comprised 79 patients who underwent additional surgery (AS) and 29 patients who did not receive AS. Five-year recurrence-free survival rates were 98.4% (95% CI: 89.3–99.8) for CR, 98.3% (95% CI: 88.8–99.8) for NCR with AS, and 73.7% (95% CI: 46.5–88.5) for NCR without AS. Lymphatic invasion and budding grade 2/3 were the major risk factors for recurrence, with hazard ratios of 40.7 (p < 0.001) and 23.1 (p = 0.007), respectively. Of the patients in the NCR group without AS, the 5-year recurrence-free rate was 85.6% (95% CI: 52.5–96.3) if there were no major risk factors (i.e., no lymphatic invasion or budding grade 2/3) (n = 21), whereas the prognosis was poor in the presence of one or more of the major risk factors, with a median recurrence-free survival and disease-specific survival of 2.5 and 3.1 years, respectively (n = 8). Discussion: In endoscopically resected T1 CRC with negative deep margins, lymphatic invasion or budding grade 2/3 may indicate a higher risk of recurrence when followed up without AS. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

9. Predictive Factors for Efficacy of Oral Tacrolimus Induction Therapy in Moderate to Severe Ulcerative Colitis Patients: Large Multicenter Retrospective Cohort Study.

Author

Oshima, Naoki, Hiraoka, Sakiko, Hayashi, Ryohei, Takahashi, Sakuma, Ishii, Manabu, Hashimoto, Shinichi, Yashima, Kazuo, Igawa, Shoko, Inokuchi, Toshihiro, Ueno, Yoshitaka, Inaba, Tomoki, Matsumoto, Hiroshi, Kawashima, Kousaku, Takami, Taro, Isomoto, Hajime, Shiotani, Akiko, Tanaka, Shinji, and Ishihara, Shunji

Published
2024
Full Text
View/download PDF

11. Efficacy and safety of 48 weeks of guselkumab for patients with Crohn's disease: maintenance results from the phase 2, randomised, double-blind GALAXI-1 trial

Author

Danese, Silvio, primary, Panaccione, Remo, additional, Feagan, Brian G, additional, Afzali, Anita, additional, Rubin, David T, additional, Sands, Bruce E, additional, Reinisch, Walter, additional, Panés, Julián, additional, Sahoo, Aparna, additional, Terry, Natalie A, additional, Chan, Daphne, additional, Han, Chenglong, additional, Frustaci, Mary Ellen, additional, Yang, Zijiang, additional, Sandborn, William J, additional, Hisamatsu, Tadakazu, additional, Andrews, Jane M, additional, D'Haens, Geert R, additional, Oliinyk, Oleksandr, additional, Bilianskyi, Leonid, additional, Gniady-Jastrzebska, Jadwiga, additional, Petryka, Robert, additional, Arlukowicz, Tomasz, additional, Gietka, Piotr, additional, Zmudzinski, Marcin, additional, Mumtaz, Syed, additional, Wolf, Douglas, additional, Wojcik, Katarzyna, additional, Duvall, George, additional, Augustyn, Monika, additional, Filip, Rafal, additional, Tarabar, Dino, additional, Tkachev, Alexander, additional, Seidler, Ursula, additional, Zittan, Eran, additional, Pokrotnieks, Juris, additional, Shchukina, Oksana, additional, Machavariani, Andro, additional, Loy, Laura, additional, Abu-farsakh, Niazy, additional, Marina, Pesegova, additional, Sreckovic, Slobodan, additional, Laclav, Martin, additional, Wei, Shu-Chen, additional, Suiter, Daniel, additional, Borsuk, Aleksey, additional, Hebuterne, Xavier, additional, Buning, Carsten, additional, Lahat-Zok, Adi, additional, Danilkiewicz, Wit, additional, Frysna, Bernadetta, additional, Jovicic, Ivana, additional, Datsenko, Olena, additional, Guram, Maninder, additional, Jain, Animesh, additional, Rashid, Zahid, additional, Heeren, Sonja, additional, Shulga, Natallia, additional, Timkin, Ivan, additional, Gornjakovic, Srdjan, additional, Lukas, Milan, additional, Altwegg, Romain, additional, Desjeux, Ariadne, additional, Reimund, Jean-Marie, additional, Giorgadze, Manana, additional, Jochum, Christoph, additional, Ito, Hiroaki, additional, Nakai, Katsuhiko, additional, Takagi, Tomohisa, additional, Zaha, Osamu, additional, Choi, Changhwan, additional, Kim, Taeoh, additional, Lee, Jonghun, additional, Stundiene, Ieva, additional, Hilmi, Ida Normiha, additional, Hj Md Said, Rosaida, additional, Leszczyszyn, Jaroslaw, additional, Abdulganieva, Diana, additional, Fominykh, Yulia, additional, Maksyashina, Svetlana, additional, Balaz, Jozef, additional, Van Domselaar, Manuel, additional, Kav, Taylan, additional, Dennis, Patrick, additional, Henry, Patricia, additional, Holmes, Robert, additional, Johnson, Christopher, additional, McBride, Matthew, additional, Sarles, Harry, additional, Moore, Gregory, additional, Yakubtsevich, Ruslan, additional, Muls, Vinciane, additional, Trbojevic, Stevan, additional, Afif, Waqqas, additional, Bernstein, Charles, additional, Klarin, Ivo, additional, Serclova, Zuzana, additional, Volfova, Miroslava, additional, Desreumaux, Pierre, additional, Gilletta de Saint Joseph, Cyrielle, additional, Roblin, Xavier, additional, Vuitton, Lucine, additional, Chelidze, Kakhaber, additional, Kuehbacher, Tanja, additional, Koutroubakis, Ioannis, additional, Cicala, Michele, additional, Fries, Walter, additional, Gasbarrini, Antonio, additional, Aoyama, Nobuo, additional, Hayashi, Yoshito, additional, Hirai, Fumihito, additional, Horiki, Norkiyuki, additional, Hoshi, Namiko, additional, Inaba, Tomoki, additional, Hiroyasu, Ishida, additional, Maemoto, Atsuo, additional, Matsumoto, Takayuki, additional, Matsushima, Kayoko, additional, Motoya, Satoshi, additional, Taruishi, Masaki, additional, Rashid, Mohammed, additional, Chun, Jaeyoung, additional, Kim, Young-Ho, additional, Park, Dong Il, additional, Sharara, Ala, additional, Jonaitis, Laimas, additional, Deriban, Gjorgi, additional, Brooker, James, additional, Gawdis-Wojnarska, Beata, additional, Wozniak-Stolarska, Barbara, additional, Andreev, Pavel, additional, Simanenkov, Vladimir, additional, Trofimov, Vasiliy, additional, Jovanovic, Igor, additional, Zdravkovic, Natasa, additional, Aldeguer i Mante, Xavier, additional, Hernandez Ramirez, Vicent, additional, Akpinar, Hale, additional, Celebi, Gurkan, additional, Hamzaoglu, Hulya, additional, Fernandez, Juan, additional, Kamath, Jayaprakash, additional, Palekar, Nicole, additional, Pruthi, Jatinder S., additional, Rausher, David, additional, and Ritter, Timothy, additional

Published
2024
Full Text
View/download PDF

12. Correction to: Effectiveness of second-look endoscopy after gastric endoscopic submucosal dissection in patients taking antithrombotic agents: a multicenter propensity score matching analysis

Author

Iwatsubo, Taro, Takeuchi, Toshihisa, Hakoda, Akitoshi, Fujiwara, Yasuhiro, Nagami, Yasuaki, Naito, Yuji, Dohi, Osamu, Tatsuta, Tetsuya, Sawaya, Manabu, Jin, Xiaoyi, Koike, Tomoyuki, Sugimoto, Mitsushige, Murata, Masaki, Hamada, Kenta, Okada, Hiroyuki, Kobara, Hideki, Chiyo, Taiga, Yoshida, Norimasa, Tomatsuri, Naoya, Inaba, Tomoki, Ishikawa, Shigenao, Nagahara, Akihito, Ueyama, Hiroya, Koizumi, Eriko, Iwakiri, Katsuhiko, Mizukami, Kazuhiro, Murakami, Kazunari, Furuta, Takahisa, Suzuki, Takahiro, Ogasawara, Naotaka, Kasugai, Kunio, Isomoto, Hajime, Kawaguchi, Koichiro, Shibagaki, Kotaro, Kataoka, Hiromi, Shimura, Takaya, Suzuki, Hidekazu, Nishizawa, Toshihiro, and Higuchi, Kazuhide

Published
2022
Full Text
View/download PDF

15. Lesion size, elevated morphology, and non or closed-type atrophy are predictive factors for gastric adenocarcinoma of the fundic gland type rather than oxyntic gland adenoma

Author

Iwamuro, Masaya, Kusumoto, Chiaki, Nakagawa, Masahiro, Matsueda, Kazuhiro, Kobayashi, Sayo, Yoshioka, Masao, Inaba, Tomoki, Toyokawa, Tatsuya, Sakaguchi, Chihiro, Tanaka, Shouichi, Tanaka, Takehiro, and Okada, Hiroyuki

Subjects
oxyntic gland adenoma, Gastric adenocarcinoma of the fundic gland type (GA-FG), Oncology, gastric neoplasms, submucosal invasion, Gastroenterology
Abstract

Background: An oxyntic gland neoplasm confined to the mucosal layer (T1a) is classified as an oxyntic gland adenoma, whereas that with submucosal invasion (T1b) is defined as gastric adenocarcinoma of the fundic gland type (GA-FG). Methods: To reveal the differences in clinical features between them, we retrospectively investigated 136 patients with 150 oxyntic gland adenoma and GA-FG lesions. Results: The univariate analysis revealed that the mean size (GA-FG vs. oxyntic gland adenoma, 7.7±5.4 vs. 5.5±3.1 mm), the prevalence of elevated morphology (79.1% vs. 51.8%), black pigmentation within the lesion (23.9% vs. 9.6%), and non or closed-type atrophy (81.2% vs. 65.1%) were different between the two groups. A multivariate logistic regression analysis revealed that ≥5 mm lesion size (odds ratio, 2.96; 95% confidence interval: 1.21–7.23), elevated morphology (odds ratio, 2.40; 95% confidence interval: 1.06–5.45), and no or closed-type atrophy (odds ratio, 2.49; 95% confidence interval: 1.07–5.80) were factors in distinguishing GA-FG from oxyntic gland adenoma. When oxyntic gland neoplasms with no or one feature were judged as oxyntic gland adenomas and those with two or three features were judged as GA-FG, the sensitivity and specificity were 85.1% and 43.4% for GA-FG, respectively. Conclusions: We identified three possible distinctive features of GA-FG compared to oxyntic gland adenoma: lesion size ≥5 mm, elevated morphology, and no or closed-type atrophy.

Published
2023

17. Results of the interim analysis of a prospective, multicenter, observational study of small subepithelial lesions in the stomach.

Author

Iwamuro, Masaya, Mitsuhashi, Toshiharu, Inaba, Tomoki, Matsueda, Kazuhiro, Nagahara, Teruya, Takeuchi, Yoji, Doyama, Hisashi, Mizuno, Masakatsu, Yada, Tomoyuki, Kawai, Yoshinari, Nakamura, Jun, Matsubara, Minoru, Nebiki, Hiroko, Niimi, Keiko, Toyokawa, Tatsuya, Takenaka, Ryuta, Takeda, Sho, Tanaka, Shouichi, Nishimura, Mamoru, and Tsuzuki, Takao

Subjects
SCIENTIFIC observation, STOMACH, NATURAL history, TUMOR surgery, GASTROINTESTINAL stromal tumors
Abstract

Objectives: Long‐term outcomes of gastric subepithelial lesions have not been elucidated. To reveal the natural history, we initiated a prospective, 10‐year follow‐up of patients with small (≤20 mm) gastric subepithelial lesions in September 2014. Here, we report the results of an interim analysis of a prospective observational study. Methods: In total, 567 patients with 610 lesions were prospectively registered between September 2014 and August 2016. The location, size, morphology, and number of subepithelial lesions were recorded on a web‐based case report form. This study has been conducted as an Academic Committee Working Group of the Japan Gastroenterological Endoscopy Society. Results: The endoscopic follow‐up period was 4.60 ± 1.73 years (mean ± standard deviation), and survival data were investigated for 5.28 ± 1.68 years. This interim analysis revealed that the estimated cumulative incidence of a size increase ≥5 mm, after accounting for patients' death and resection of the tumor as competing risk events, was 4.5% at 5 years. In addition, the estimated cumulative incidence of lesion size increase ≥5 mm or resection of lesions was 7.9% at 5 years, and that of size increase ≥10 mm or resection of lesions was 4.5% at 5 years. Conclusion: These results indicate that approximately one in 13 patients with small (≤20 mm) gastric subepithelial lesions may require resection or further investigation for increased tumor size (≥5 mm) within 5 years. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

18. Predictive Factors for Efficacy of Oral Tacrolimus Induction Therapy in Moderate to Severe Ulcerative Colitis Patients: Large Multicenter Retrospective Cohort Study

Author

Oshima, Naoki, primary, Hiraoka, Sakiko, additional, Hayashi, Ryohei, additional, Takahashi, Sakuma, additional, Ishii, Manabu, additional, Hashimoto, Shinichi, additional, Yashima, Kazuo, additional, Igawa, Shoko, additional, Inokuchi, Toshihiro, additional, Ueno, Yoshitaka, additional, Inaba, Tomoki, additional, Matsumoto, Hiroshi, additional, Kawashima, Kousaku, additional, Takami, Taro, additional, Isomoto, Hajime, additional, Shiotani, Akiko, additional, Tanaka, Shinji, additional, and Ishihara, Shunji, additional

Published
2023
Full Text
View/download PDF

19. Results of the interim analysis of a prospective, multicenter, observational study of small subepithelial lesions in the stomach

Author

Iwamuro, Masaya, primary, Mitsuhashi, Toshiharu, additional, Inaba, Tomoki, additional, Matsueda, Kazuhiro, additional, Nagahara, Teruya, additional, Takeuchi, Yoji, additional, Doyama, Hisashi, additional, Mizuno, Masakatsu, additional, Yada, Tomoyuki, additional, Kawai, Yoshinari, additional, Nakamura, Jun, additional, Matsubara, Minoru, additional, Nebiki, Hiroko, additional, Niimi, Keiko, additional, Toyokawa, Tatsuya, additional, Takenaka, Ryuta, additional, Takeda, Sho, additional, Tanaka, Shouichi, additional, Nishimura, Mamoru, additional, Tsuzuki, Takao, additional, Akahoshi, Kazuya, additional, Furuta, Takahisa, additional, Haruma, Ken, additional, and Okada, Hiroyuki, additional

Published
2023
Full Text
View/download PDF

21. AJM300 (carotegrast methyl), an oral antagonist of α4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

Author

Matsuoka, Katsuyoshi, primary, Watanabe, Mamoru, additional, Ohmori, Toshihide, additional, Nakajima, Koichi, additional, Ishida, Tetsuya, additional, Ishiguro, Yoh, additional, Kanke, Kazunari, additional, Kobayashi, Kiyonori, additional, Hirai, Fumihito, additional, Watanabe, Kenji, additional, Mizusawa, Hidehiro, additional, Kishida, Shuji, additional, Miura, Yoshiharu, additional, Ohta, Akira, additional, Kajioka, Toshifumi, additional, Hibi, Toshifumi, additional, Motoya, Satoshi, additional, Maemoto, Atsuo, additional, Fujiya, Mikihiro, additional, Ashida, Toshifumi, additional, Goto, Mitsuru, additional, Matsumoto, Takayuki, additional, Suzuki, Yasuo, additional, Hamahata, Yukihiro, additional, Nakagawa, Tomoo, additional, Kato, Naoya, additional, Kato, Jun, additional, Endo, Yutaka, additional, Suzuki, Ryoichi, additional, Matsuda, Koichiro, additional, Ohmiya, Naoki, additional, Katsushima, Shinji, additional, Hosomi, Shuhei, additional, Tarumi, Ken-ichi, additional, Watanabe, Chiyuki, additional, Saito, Mitsuru, additional, Yokoyama, Yuichiro, additional, Inaba, Tomoki, additional, Sakata, Yasuhisa, additional, Hongo, Hitoshi, additional, Shibuya, Tomoyoshi, additional, Kawakami, Kazuhiko, additional, Kakuta, Yoichi, additional, Irisawa, Atsushi, additional, Yoshimura, Naoki, additional, Fukuda, Katsuyuki, additional, Shirai, Takayuki, additional, Ichikawa, Hitoshi, additional, Nagata, Junko, additional, Suzuki, Takayoshi, additional, Yokoyama, Kaoru, additional, Tomidokoro, Takashi, additional, Kojima, Yuichiro, additional, Yamada, Masahiro, additional, Yamamoto, Hideko, additional, Yamamoto, Takayuki, additional, Horiki, Noriyuki, additional, Obata, Hirozumi, additional, Inoue, Satoko, additional, Tanaka, Shinji, additional, Toyokawa, Tatsuya, additional, Kunihiro, Masaki, additional, Hisabe, Takashi, additional, Ogata, Shinichi, additional, Takeshima, Fuminao, additional, Matsushima, Kayoko, additional, Matsuhashi, Nobuyuki, additional, Sakuraba, Hirotake, additional, Iwabuchi, Masahiro, additional, Tsuchiya, Akihiko, additional, Uchiyama, Kan, additional, Kanai, Takanori, additional, Nakamura, Masanao, additional, Yokoyama, Tadashi, additional, Hida, Nobuyuki, additional, Mitsuyama, Keiichi, additional, Osada, Taro, additional, Hiraoka, Sakiko, additional, Tsuzuki, Tomoyuki, additional, Masuo, Takashige, additional, Hokari, Ryota, additional, Kobayashi, Taku, additional, Saruta, Masayuki, additional, Araki, Masao, additional, Araki, Hiroshi, additional, Shimizu, Masahito, additional, Kikuchi, Masakazu, additional, Nishikawa, Takahiro, additional, Takedatsu, Hidetoshi, additional, Aoyagi, Kunihiko, additional, Ochiai, Toshiaki, additional, Toda, Nobuo, additional, Mizokami, Yuji, additional, Nagahori, Masakazu, additional, Matsueda, Kazuhiro, additional, Kino, Hitoshi, additional, Kanamori, Akira, additional, Suzuki, Tsunehiro, additional, Sakurai, Toshiharu, additional, Kudo, Masatoshi, additional, Kitano, Atsuo, additional, Hisamatsu, Tadakazu, additional, Kumagai, Shinji, additional, Ninomiya, Tomoyuki, additional, Mori, Kenichiro, additional, Yoshida, Shun-ichi, additional, and Goto, Mitsuhide, additional

Published
2022
Full Text
View/download PDF

22. Nonrecurrence Rate of Underwater EMR for ≤20-mm Nonampullary Duodenal Adenomas: A Multicenter Prospective Study (D-UEMR Study)

Author

Yamasaki, Yasushi, primary, Uedo, Noriya, additional, Akamatsu, Takuji, additional, Kagawa, Tomo, additional, Higashi, Reiji, additional, Dohi, Osamu, additional, Furukawa, Masanori, additional, Takahashi, Yu, additional, Inoue, Takuya, additional, Tanaka, Shouichi, additional, Takenaka, Ryuta, additional, Iguchi, Mikitaka, additional, Kawamura, Takuji, additional, Tsuzuki, Takao, additional, Yamasaki, Tomoaki, additional, Yamashina, Takeshi, additional, Nasu, Junichiro, additional, Mannami, Tomohiko, additional, Yamauchi, Atsushi, additional, Matsueda, Kazuhiro, additional, Aizawa, Shigeyuki, additional, Mitsuhashi, Toshiharu, additional, Okada, Hiroyuki, additional, Kanzaki, Hiromitsu, additional, Inoue, Shuntaro, additional, Miyake, Muneaki, additional, Ohmori, Masayasu, additional, Takeuchi, Yoji, additional, Tani, Yasuhiro, additional, Harada, Nobuyuki, additional, Agatsuma, Nobukazu, additional, Okada, Keijirou, additional, Ikenouchi, Maiko, additional, Nakatani, Yasuki, additional, Uenoyama, Yoshito, additional, Yamashita, Yukitaka, additional, Ishikawa, Shigenao, additional, Inaba, Tomoki, additional, Miyahara, Koji, additional, Moritou, Yuki, additional, Nakagawa, Masahiro, additional, Kitae, Hiroaki, additional, Ishida, Tsugitaka, additional, Naito, Yuji, additional, Nishio, Akiyoshi, additional, Shimatani, Masaaki, additional, Kato, Ryo, additional, Taki, Shinya, additional, Mandai, Koichiro, additional, Sanada, Kasumi, additional, Nakase, Kojiro, additional, Nebiki, Hiroko, additional, Saito, Shunsuke, additional, Wakatsuki, Toshiyuki, additional, and Nishimura, Naoyuki, additional

Published
2022
Full Text
View/download PDF

23. Additional file 1 of Endoscopic features of oxyntic gland adenoma and gastric adenocarcinoma of the fundic gland type differ between patients with and without Helicobacter pylori infection: a retrospective observational study

Author

Iwamuro, Masaya, Kusumoto, Chiaki, Nakagawa, Masahiro, Matsueda, Kazuhiro, Kobayashi, Sayo, Yoshioka, Masao, Inaba, Tomoki, Toyokawa, Tatsuya, Sakaguchi, Chihiro, Tanaka, Shouichi, Tanaka, Takehiro, and Okada, Hiroyuki

Abstract

Additional file 1. Table S1. Comparison of the active and inactive gastritis groups.

Published
2022
Full Text
View/download PDF

24. Endoscopic Features of Oxyntic Gland Adenoma and Gastric Adenocarcinoma of the Fundic Gland Type Differ Between Patients with and Without Helicobacter pylori Infection: A Retrospective Observational Study

Author

Iwamuro, Masaya, primary, Kusumoto, Chiaki, additional, Nakagawa, Masahiro, additional, Matsueda, Kazuhiro, additional, Kobayashi, Sayo, additional, Yoshioka, Masao, additional, Inaba, Tomoki, additional, Toyokawa, Tatsuya, additional, Sakaguchi, Chihiro, additional, Tanaka, Shouichi, additional, Tanaka, Takehiro, additional, and Okada, Hiroyuki, additional

Published
2022
Full Text
View/download PDF

25. Dasatinib-induced colitis: clinical, endoscopic and histological findings

Author

Yamauchi, Kenji, primary, Inaba, Tomoki, additional, Colvin, Hugh Shunsuke, additional, Sakakihara, Ichiro, additional, Yamamoto, Kumiko, additional, Izumikawa, Koichi, additional, Takahashi, Sakuma, additional, Tanaka, Shigetomi, additional, Ishikawa, Shigenao, additional, Wato, Masaki, additional, Ando, Midori, additional, and Waki, Masato, additional

Published
2022
Full Text
View/download PDF

26. Risk factors and prediction of bleeding after gastric endoscopic submucosal dissection in patients on anti­thrombotic therapy: newly developed bleeding prediction application software, SAMURAI model

Author

Hakoda, Akitoshi, primary, Takeuchi, Toshihisa, additional, Kojima, Yuichi, additional, Fujiwara, Yasuhiro, additional, Nagami, Yasuaki, additional, Naito, Yuji, additional, Fukuda, Shinsaku, additional, Koike, Tomoyuki, additional, Sugimoto, Mitsushige, additional, Hamada, Kenta, additional, Kobara, Hideki, additional, Yoshida, Norimasa, additional, Inaba, Tomoki, additional, Nagahara, Akihito, additional, Koizumi, Eriko, additional, Murakami, Kazunari, additional, Furuta, Takahisa, additional, Ogasawara, Naotaka, additional, Isomoto, Hajime, additional, Shibagaki, Kotaro, additional, Kataoka, Hiromi, additional, Suzuki, Hidekazu, additional, and Higuchi, Kazuhide, additional

Published
2022
Full Text
View/download PDF

27. SIGNIFICANCE OF EUS IN THE FOLLOW-UP OF SMALL SUBEPITHELIAL LESIONS IN THE STOMACH: A PROSPECTIVE, MULTICENTER, OBSERVATIONAL STUDY.

Author

Nebiki, Hiroko, Iwamuro, Masaya, Inaba, Tomoki, Matsueda, Kazuhiro, Takeuchi, Yoji, Nagahara, Teruya, Doyama, Hisashi, Mizuno, Masakatsu, Yada, Tomoyuki, Kawai, Yoshinari, Nakamura, Jun, Matubara, Minoru, Toyokawa, Tatsuya, Takenaka, Ryuta, Takeda, Sho, Tanaka, Shouichi, Nishimura, Mamoru, Tsuzuki, Takao, Akahoshi, Kazuya, and Fujishiro, Mitsuhiro

Published
2024
Full Text
View/download PDF

29. Efficacy and safety of a new vedolizumab subcutaneous formulation in Japanese patients with moderately to severely active ulcerative colitis

Author

Kobayashi, Taku, primary, Ito, Hiroaki, additional, Ashida, Toshifumi, additional, Yokoyama, Tadashi, additional, Nagahori, Masakazu, additional, Inaba, Tomoki, additional, Shikamura, Mitsuhiro, additional, Yamaguchi, Takayoshi, additional, Hori, Tetsuharu, additional, Pinton, Philippe, additional, Watanabe, Mamoru, additional, and Hibi, Toshifumi, additional

Published
2021
Full Text
View/download PDF

30. Risk factors for postgastric endoscopic submucosal dissection bleeding in direct oral anticoagulant users.

Author

Kagawa, Tomo, Ishikawa, Shigenao, Hidaka, Yu, Colvin, Hugh Shunsuke, Nakanishi, Akira, Ohkawa, Jumpei, Negishi, Shin, Yasutomi, Eriko, Yamauchi, Kenji, Okamoto, Kunio, Sakakihara, Ichiro, Izumikawa, Koichi, Yamamoto, Kumiko, Takahashi, Sakuma, Tanaka, Shigetomi, Matsuura, Mihoko, Wato, Masaki, Hasui, Toshimi, and Inaba, Tomoki

Abstract

Objectives Methods Results Conclusions Bleeding after endoscopic submucosal dissection (ESD) for gastric tumors in patients taking antithrombotic drugs, in particular direct oral anticoagulants (DOACs), remains unresolved; therefore, we evaluated the risk factors for post‐ESD bleeding and drug differences in patients taking DOACs.We included 278 patients taking antithrombotic drugs who underwent gastric ESD between January 2017 and March 2022. Antithrombotic drugs were withdrawn following the 2017 guidelines (Appendix on anticoagulants including DOACs). To further clarify differences in antithrombotic agents' effects, the peri‐cancerous mucosa in the resected specimen was pathologically evaluated according to the Updated Sydney System. Multivariate analysis was performed to assess the risk of post‐ESD bleeding.The incidence of post‐ESD bleeding in patients taking DOACs was 19.6% (10/51). Among patients taking antithrombotic drugs, DOACs were identified as a possible factor involved in post‐ESD bleeding (odds ratio [OR] 4.92). Among patients taking DOACs, possible factors included resection length diameter ≥30 mm (OR 3.72), presence of neutrophil infiltration (OR 2.71), lesions occurring in the lower third of stomach (OR 2.34), and preoperative antiplatelet use (OR 2.22). Post‐ESD bleeding by DOAC type was 25.0% of patients (4/16) receiving apixaban, in 20.0% (3/15) receiving edoxaban, in 21.4% (3/14) receiving rivaroxaban, and in none of those receiving dabigatran.The administration of DOACs was shown to be a possible factor involved in post‐ESD bleeding, and risk factors for patients taking DOACs included neutrophil infiltration. The pharmacological differences in the effects of DOACs contributing to bleeding in gastric ulcers suggest comparatively less bleeding with dabigatran after ESD. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

31. [Cystic duct carcinoma in a patient with a history of cholecystectomy: a case report].

Author

Sakakihara I, Wato M, Ishihama S, Hugh Colvin S, Kagawa T, Izumikawa K, Takahashi S, Tanaka S, Ishikawa S, and Inaba T

Subjects
Male, Humans, Aged, 80 and over, Cystic Duct diagnostic imaging, Cystic Duct surgery, Cystic Duct pathology, Cholecystectomy, Cholangiopancreatography, Endoscopic Retrograde, Cholecystectomy, Laparoscopic, Gallstones pathology, Gallstones surgery, Adenocarcinoma diagnosis
Abstract

An 83-year-old Japanese man who underwent cholecystectomy for cholecystolithiasis 17 years ago visited our hospital owing to epigastric pain. He was initially diagnosed with choledocholithiasis and acute cholangitis following white blood cell, C-reactive protein, total bilirubin, alkaline phosphatase, and γ-glutamyltranspeptidase level elevations along with common bile duct stones on computed tomography (CT). Moreover, CT, magnetic resonance imaging, endoscopic retrograde cholangiography (ERC), and endoscopic ultrasonography (EUS) also revealed a 2-cm-diameter mass arising from the remnant cystic duct. The cytology of the bile at the time of ERC was not conclusive. However, EUS-assisted fine needle aspiration (EUS-FNA) of the mass confirmed the diagnosis of adenocarcinoma of the remnant cystic duct. The patient underwent extrahepatic bile duct resection. Cystic duct carcinoma following cholecystectomy is rare. We report a case diagnosed by EUS-FNA.

Published
2024
Full Text
View/download PDF

32. Risk factors and prediction of bleeding after gastric endoscopic submucosal dissection in patients on antithrombotic therapy: newly developed bleeding prediction application software, SAMURAI model.

Author

Hakoda A, Takeuchi T, Kojima Y, Fujiwara Y, Nagami Y, Naito Y, Fukuda S, Koike T, Sugimoto M, Hamada K, Kobara H, Yoshida N, Inaba T, Nagahara A, Koizumi E, Murakami K, Furuta T, Ogasawara N, Isomoto H, Shibagaki K, Kataoka H, Suzuki H, and Higuchi K

Abstract

Bleeding after gastric endoscopic submucosal dissection (ESD) remains problematic, especially in patients receiving antithrombotic therapy. Therefore, this study aimed to identify the risk factors. In this retrospective study, patients ( n  = 1,207) who underwent gastric ESD while receiving antithrombotic therapy were enrolled at Osaka Medical and Pharmaceutical University Hospital and 18 other referral hospitals in Japan. Risks of post-ESD bleeding were calculated using multivariable logistic regression. The dataset was divided into a derivation cohort and a validation cohort. We created a prediction model using the derivation cohort. The accuracy of the model was evaluated using the validation cohort. Post-ESD bleeding occurred in 142 (11.8%) participants. Multivariable analysis yielded an odds ratio of 2.33 for aspirin, 4.90 for P2Y12 receptor antagonist, 1.79 for cilostazol, 0.95 for other antithrombotic agents, 6.53 for warfarin, 5.65 for dabigatran, 7.84 for apixaban, 10.45 for edoxaban, 6.02 for rivaroxaban, and 1.46 for heparin bridging. The created prediction model was called safe ESD management using the risk analysis of post-bleeding in patients with antithrombotic therapy (SAMURAI). This model had good predictability, with a C-statistic of 0.77. In conclusion, use of the SAMURAI model will allow proactive management of post-ESD bleeding risk in patients receiving antithrombotic therapy., Competing Interests: No potential conflicts of interest were disclosed., (Copyright © 2022 JCBN.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results